Pluristem Director Dr. Liat Flaishon Interviewed on CorporateProfile.com
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 06/14/12 -- Corporate Profile, LLC announced today that Pluristem Therapeutics, Inc. (NASDAQ: PSTI) (TASE: PLTR) Director Dr. Liat Flaishon, was interviewed on
The video can be viewed at: and
Pluristem Therapeutics Inc. (NASDAQ: PSTI) (TASE: PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem is focusing on the use of PLX cells administered locally.
Data from two phase I/II studies indicate that Pluristem's first PLX product candidate, PLX-PAD, is safe and potentially effective treatment of end stage peripheral artery disease when given locally. Additionally, Pluristem is developing PLX-PAD for cardiac ischemia, PLX-BMP for Acute Radiation Exposure, Bone Marrow Transplant Failure and Chemotherapy induced Bone Marrow Aplasia, PLX-ORTHO for orthopedic indications and PLX-PAH for Pulmonary Hypertension in collaboration with United Therapeutics. Pluristem's pre-clinical animal models have demonstrated PLX cells are potentially effective in inflammatory/ischemic indications, including diastolic heart failure.
For more information, visit
CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in a unique platform for investors to receive today's hottest tips and market info.
Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.06.2012 - 10:41 Uhr
Sprache: Deutsch
News-ID 1124544
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Information Services
Anmerkungen:
Diese Pressemitteilung wurde bisher 148 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pluristem Director Dr. Liat Flaishon Interviewed on CorporateProfile.com
"
steht unter der journalistisch-redaktionellen Verantwortung von
Corporate Profile LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
